Darya Novopashina

Dr. Darya Novopashina

orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 December 2013 in Molecules
Verified
Journal Article
Open access
PDF file
ABAlexandre Boutorine
Alexandre Boutorine
DNDarya Novopashina
Darya Novopashina
OKOlga Krasheninina
Olga Krasheninina
KNKarine Nozeret
Karine Nozeret
AVAlya Venyaminova
Alya Venyaminova
This review analyses the literature concerning non-fluorescent and fluorescent probes for nucleic acid imaging in fixed and living cells from the point of view of their suitability for imaging intracellular native RNA and DNA. Attention is mainly paid to fluorescent probes for fluorescence microscopy imaging. Requirements for the target-binding part and the fluorophore making up the probe are formulated. In the case of native double-stranded DNA, structure-specific and sequence-specific probes are discussed. Among the latest, three classes of dsDNA-targeting molecules are described: (i) sequence-specific peptides and proteins; (ii) triplex-forming oligonucleotides and (iii) polyamide oligo(N-methylpyrrole/N-methylimidazole) minor groove binders. Polyamides seem to be the most promising targeting agents for fluorescent probe design, however, some technical problems remain to be solved, such as the relatively low sequence specificity and the high background fluorescence inside the cells. Several examples of fluorescent probe applications for DNA imaging in fixed and living cells are cited. In the case of intracellular RNA, only modified oligonucleotides can provide such sequence-specific imaging. Several approaches for designing fluorescent probes are considered: linear fluorescent probes based on modified oligonucleotide analogs, molecular beacons, binary fluorescent probes and template-directed reactions with fluorescence probe formation, FRET donor-acceptor pairs, pyrene excimers, aptamers and others. The suitability of all these methods for living cell applications is discussed.

1 May 2015 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
VDVolha Dzmitruk
Volha Dzmitruk
ASAleksandra Szulc
Aleksandra Szulc
DSDzmitry Shcharbin
Dzmitry Shcharbin
AJAnna Janaszewska
Anna Janaszewska
NSNatallia Shcharbina
Natallia Shcharbina
MBMaria Bryszewska
Maria Bryszewska

1 May 2015 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
Maksim IonovMaksim Ionov
Maksim Ionov
JLJoanna Lazniewska
Joanna Lazniewska
VDVolha Dzmitruk
Volha Dzmitruk
IHInessa Halets
Inessa Halets
SLSvetlana Loznikova
Svetlana Loznikova
MBMaria Bryszewska
Maria Bryszewska

30 November 2017 in Molecules
Verified
Journal Article
Open access
PDF file
OKOlga Krasheninina
Olga Krasheninina
DNDarya Novopashina
Darya Novopashina
Evgeny ApartsinEvgeny Apartsin
Evgeny Apartsin
AVAlya Venyaminova
Alya Venyaminova
In this review, we summarize the recent advances in the use of pyrene-modified oligonucleotides as a platform for functional nucleic acid-based constructs. Pyrene is of special interest for the development of nucleic acid-based tools due to its unique fluorescent properties (sensitivity of fluorescence to the microenvironment, ability to form excimers and exciplexes, long fluorescence lifetime, high quantum yield), ability to intercalate into the nucleic acid duplex, to act as a π-π-stacking (including anchoring) moiety, and others. These properties of pyrene have been used to construct novel sensitive fluorescent probes for the sequence-specific detection of nucleic acids and the discrimination of single nucleotide polymorphisms (SNPs), aptamer-based biosensors, agents for binding of double-stranded DNAs, and building blocks for supramolecular complexes. Special attention is paid to the influence of the design of pyrene-modified oligonucleotides on their properties, i.e., the structure-function relationships. The perspectives for the applications of pyrene-modified oligonucleotides in biomolecular studies, diagnostics, and nanotechnology are discussed.

Verified
Journal Article
Open access
PDF file
MVMariya A. Vorobyeva
Mariya A. Vorobyeva
MDMaya A. Dymova
Maya A. Dymova
DNDarya Novopashina
Darya Novopashina
EKElena Kuligina
Elena Kuligina
VTValentina Timoshenko
Valentina Timoshenko
AVAlya Venyaminova
Alya Venyaminova
Boron neutron capture therapy (BNCT) is a binary radiotherapeutic approach to the treatment of malignant tumors, especially glioblastoma, the most frequent and incurable brain tumor. For successful BNCT, a boron-containing therapeutic agent should provide selective and effective accumulation of 10B isotope inside target cells, which are then destroyed after neutron irradiation. Nucleic acid aptamers look like very prospective candidates for carrying 10B to the tumor cells. This study represents the first example of using 2′-F-RNA aptamer GL44 specific to the human glioblastoma U-87 MG cells as a boron delivery agent for BNCT. The closo-dodecaborate residue was attached to the 5′-end of the aptamer, which was also labeled by the fluorophore at the 3′-end. The resulting bifunctional conjugate showed effective and specific internalization into U-87 MG cells and low toxicity. After incubation with the conjugate, the cells were irradiated by epithermal neutrons on the Budker Institute of Nuclear Physics neutron source. Evaluation of the cell proliferation by real-time cell monitoring and the clonogenic test revealed that boron-loaded aptamer decreased specifically the viability of U-87 MG cells to the extent comparable to that of 10B-boronophenylalanine taken as a control. Therefore, we have demonstrated a proof of principle of employing aptamers for targeted delivery of boron-10 isotope in BNCT. Considering their specificity, ease of synthesis, and large toolkit of chemical approaches for high boron-loading, aptamers provide a promising basis for engineering novel BNCT agents.

15 March 2021 in Frontiers in Chemistry
Verified
Journal Article
Open access
DNDarya Novopashina
Darya Novopashina
MVMariya Alexandrovna Vorobyeva
Mariya Alexandrovna Vorobyeva
AVAlya Venyaminova
Alya Venyaminova
Boron clusters attract considerable attention as promising therapeutic tools for boron neutron capture therapy (BNCT). They combine high boron content with high chemical and biological stability, biorthogonality, and low toxicity. The development of oligonucleotide-based constructs and nucleic acid-like molecules, such as oligomeric phosphate diesters, bearing one or multiple boron clusters permits to create potential high boron-loaded agents for BNCT with good bioavailability, specifically interacting with nucleic acids inside the cell. Here, we shortly review the strategies and solutions in the design of oligonucleotide conjugates with boron clusters in light of the requirements for effective BNCT and future prospects of their practical use.